Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice by Jin, L et al.
Human thyroid tumours, the puzzling lessons from E7 and
RET/PTC3 transgenic mice
L Jin*,1, A Burniat
1, J-E Dumont
1, F Miot
1, B Corvilain
1 and B Franc
2
1Institut de Recherche Interdisciplinaire (IRIBHM), Faculte ´ de Me ´decine, Universite ´ Libre de Bruxelles (ULB), Campus Erasme, Route de Lennik 808,
B 1070 Bruxelles, Belgique;
2Ho ˆpital Ambroise Pare ´ (APHP), Universite ´ de Versailles Saint Quentin en Yvelines, Service d’Anatomie Pathologique, 9 Av.,
Charles de Gaulle, F-92104 Boulogne, France
Human rearranged RET/PTC3 (papillary thyroid carcinoma) proto-oncogene and high-risk human papillomavirus (HPV) type 16 E7
oncogene induces in the mouse a neoplastic transformation of thyroid follicular cells. We present a detailed immuno-histological study
(170 mouse thyroids: RET/PTC3, E7, wild type, 2- to 10-month-old) with cell cycle proliferation and signalling pathway indicators. The
characteristics of both models are different. There is an ‘oncogene dependent’ cellular signature, maintained at all studied ages in the E7
model, less in the RET/PTC3 model. During tumour development a large heterogeneity occurred in the Tg-RET/PTC3 model within a
same tumour or within a same thyroid lobe. The Tg-E7 model was less heterogeneous, with a dominant goitrous pattern. The solid
tumour already described in the RET/PTC3 models associated with cribriform patterns, suggested ‘PTC spindle cell changes’ as in
humans PTC rather than the equivalent of the solid human PTC. Proliferation and apoptosis in the two thyroid models are related to
the causal oncogene rather than reflect a general tumorigenic process. The thyroids of RET/PTC3 mice appeared as a partial and
transient model of human PTCs, whereas the Tg-E7 mice do not belong to the usual PTC type.
British Journal of Cancer (2008) 99, 1874–1883. doi:10.1038/sj.bjc.6604740 www.bjcancer.com
Published online 4 November 2008
& 2008 Cancer Research UK
Keywords: cribriform patterns in thyroid tumour; RET/PTC3 and E7 transgenic mice; papillary thyroid carcinoma
                                             
Thyroid function, growth and differentiation are mainly controlled
by two pathways: the TSH-cAMP cascade and the growth factor
pathways. The oncogenic stimulations of these pathways initiate
different types of tumours (Dumont et al, 1989, 2005; Williams,
1994; Fagin, 2002; Fusco et al, 2002). To experimentally study these
diseases, different mouse models have been created.
Rearrangements of the RET tyrosine kinase receptor gene (RET/
PTCs) are found in 2.6–34% of human papillary thyroid
carcinomas (PTC) and are even more prevalent in radiation-
induced paediatric PTC (Baverstock et al, 1992; Kasakov et al,
1992). The rearranged RET/PTCs oncogene are activated forms of
the RET proto-oncogene (Fusco et al, 2002; Santoro et al, 2002).
The thyroid-targeted expression of the human RET/PTC3 onco-
gene under the control of the bovine thyroglobulin promoter in
transgenic mice, induces metastatic solid-type papillary carcino-
mas considered as analogous to the human solid-type PTC (Powell
et al, 1998).
The oncogenic properties of the high-risk human papilloma-
virus (HPV) type 16 E7 protein are attributed to its interaction
with RB1 and related proteins (Mu ¨nger et al, 1989; Weinberg, 1995;
Coulonval et al, 1997). Inactivation of these proteins results in a
continuous growth of the thyroid, little affecting its differentiation,
function and regulation (Iuliano et al, 2000). There is still a debate
on RB1 function in human thyroid tumorigenesis with contra-
dictory results on its loss or overexpression in papillary and
follicular carcinomas vs adenomas (Anwar et al, 2000).
The mice expressing the human original HPV type 16 E7 protein
under the control of the thyroglobulin promoter develop
differentiated and functionally regulated thyroid goitres, before
the occurrence of tumours mimicking human-differentiated
follicular and papillary thyroid carcinomas. In these transgenic
mice, by 1 month, follicular cells are modified, small, and
numerous with an increased nuclear/cytoplasmic ratio (Ledent
et al, 1995; Coppe ´e et al, 1996). Tumours appearing, over 1 year,
have been compared with human thyroid insular carcinomas
(Franc et al, 1998).
The coexpression of RET/PTC 3 and E7 in transgenic mouse
models lacks any cooperative effect in the neoplastic transforma-
tion of thyroid cells and the E7-induced thyroid phenotype is
dominant with respect to the RET/PTC3 one. These results are
intriguing and were poorly explained (Portella et al, 2000).
Homologies between the E7 model and several features
encountered in human benign and malignant thyroid disease have
been little explored. We know much about the pathology of RET/
PTC human tumours but much less about their biological
evolution. The meaning of solid patterns in human thyroid
tumours are a matter of debate.
We have therefore conducted a parallel study of the evolution of
gene expression and pathology in E7 and RET PTC3 mice. The
transcriptome study (Burniat et al, 2008) revealed differences of
gene expression between E7 and RETPTC3 models and between
different phases in the evolution of the tumour. The pathological
and immunohistological study presented here, in which thyroid
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were completely tested and they explain the gene expression
results. Our results permit to further explore some of the
diagnostic enigma in human thyroid pathology.
MATERIALS AND METHODS
RET/PTC3, E7 transgenic and C57Bl/6 wild-type mice were
fed with a normal iodine diet and maintained in the animal
facility under 12h light/12h darkness cycle. Animal studies
were approved by the Animal Care Use and Review Committee
(Commission d’e ´thique du Bien–Etre Animal) of the Faculty
of Medicine, Universite ´ Libre de Bruxelles (project 160N, 2007–
2010) and in compliance with the UKCCCR guidelines on
animal use.
Experimental groups consist of E7 mice (n¼87), RET/PTC3
mice (n¼53) and the C57Bl/6 mice (n¼30) served as controls.
RET/PTC3 and E7 transgenic mice provided by Dr M Santoro
(Napoli) and Dr C Ledent (our Institute) respectively were crossed
with wild type C57Bl/6. Both strain progenies were genotyped by
PCR (Burniat et al, 2008).
Genomic DNA was prepared from a piece (0.5cm) of tail by a
lysis treatment at 551C in TNES (100mM Tris-HCl pH 8/200mM
NaCl/5mM EDTA/0.2% SDS/40mg proteinase K). Selected regions
of the human RET and E7 genes were amplified by the PCR
method. The primers used for the amplification were: RET
forward, 50-GGCCAGAGCCCTAAGGAGGGC-30; RET reverse,
50-AAGGGATTCAATTGCCATCCA-30. E7 forward, 50-CATGCAT
GGAGATACACCT-30; E7 reverse, 50-GATTATGGTTTCTGAGAACA-30.
Amplified products were visualized on agarose gel as 1500 and
300bp bands respectively.
The antibodies used to test thyroid function were: anti-Tg
polyclonal antibody (Dako, Glostrup, Denmark), anti-Tg-I mono-
clonal antibody B1 (gift from Dr C Ris-Stalpers), anti-NIS rabbit
polyclonal antibody (gift from Dr N Carrasco), cell proliferation
and signalling pathways: anti-BrdU monoclonal mouse antibody
(Becton Dickinson, Rutherford, NJ, USA), anti-Ki-67 monoclonal
rat antibody (clone TEC-3, Dako), anti-Cyclin D1 monoclonal
rabbit antibody (SP4, NeoMarkers, Fremont, CA, USA); anti-
Phospho-p44/42 MAPK Thr202/Tyr204 monoclonal rabbit anti-
body (20G11, Cell Signalling, Danvers, MA, USA), anti-Phospho-
Akt Ser473 monoclonal rabbit monoclonal antibody (736E11, Cell
Signaling). Primary antibodies, dilution and incubation time are
listed in Table 1.
Immunohistochemistry, radioiodide uptake, and
proliferation index determination
The transgenic and control mice were killed at 2, 6 and 10 months
of age and thyroids were removed for pathological examination.
One or both lobes were fixed in 4% paraformaldehyde and
embedded in paraffin by standard procedures.
For determination of radioiodide uptake, mice were injected
intraperitoneally (i.p.) with 0.5mCikg
 1 body weight Na
125I (IMS
30; PerkinElmer Life and Analytical Sciences, Boston, MA, USA) in
physiological serum. Twenty-four hours after
125I injection, they
were perfused with 0.9% NaCl during 15min before killing. After
deparaffinisation and rehydratation, the slides were dipped two
times in 421C NTB3 Emulsion (Kodak), stored in light tight box at
41C for 8 days, developed with Kodak D-19 Developer and stained
with haematoxylin–eosin (H&E).
For determination of the proliferation index, 5-Bromo-20-
deoxyuridine (BrdU, Sigma, Saint Louis, MO, USA) 0.5mgg
 1
body weight was injected i.p. 24h before killing. The thyroids were
fixed in Clarke’s fixative (75% V/V ethanol: 25% V/V glacial acetic
acid) 18h after perfusion of the mice, embedded in paraffin. BrdU
was detected by immunohistochemistry. DNA in the samples was
denatured in two N HCl, followed by neutralization in 0.1 M borate
buffer, pH 8.5.
For immunohistochemical analysis of protein expression, the
endogenous peroxidase activity was quenched by a treatment with
6% H2O2 in absolute methanol; non-specific-binding sites were
blocked with 10% normal goat serum for Tg and Tg-I, normal
horse serum for others. After incubation with primary antibodies,
tissue sections were sequentially incubated with second antibodies
conjugated to peroxidase-labelled polymer (EnVision detection,
Dako) for Tg and Tg-I or goat biotinylated secondary antibodies
(Jackson ImmunoResearch, West Grove, PA, USA) (Table 1) and
Avidin-conjugated horseradish peroxidase ABC system (Dako) for
others. Staining was developed with aminoethylcarbazole-AEC
(Dako) and diaminobenzidine-DAB (Dako) substrates (Table 1)
and sections were slightly counterstained with Mayer’s haematox-
ylin. Negative controls were performed using a replacement of the
first antibodies with a blocking solution.
The BrdU, Ki-67, and Cyclin D1 labelling index values were
evaluated by counting the number of immunopositive cells out of a
total of thousand cells (Mean±s.e.m.). At least two different slides
from the same mouse thyroid were counted.
RESULTS
The thyroids of all the mice used presented a similar level of E7 or
RET/PTC mRNA transgene expression by RT–PCR (not shown).
When compared with the wild type (WT) taken as control, RET/
PTC3 and Tg-E7 transgenic mice thyroid harboured two different
phenotypes. According to age, the Tg-E7 model evolved on a
predominant goitrous mode with no tumour formation, whereas
tumour formation occurred in 28% of the RET/PTC3 mice at 6 and
10 months. A hyperplastic background occurred in both models
with peculiar characteristics in the RET/PTC3 model.
The dominant feature at the cellular level was the occurrence of
‘oncogene-dependent’ follicular cell changes, leading to different
cellular phenotypes, small cells in the E7 model and large cells in
the RET/PTC3 model, which evolved differently with time.
Table 1 Detection of thyroid-specific, cell cycle and cell pathway proteins
Antibodies Incubation time Dilution Second antibody Revelation substrate
Nis Overnight 1/40000 Polyclonal Ab anti-Ig-HRP DAB
Tg 3h 1/3000 EnVision rabbit AEC
Tg-I Overnight 1/2000 EnVision mouse AEC
Ki-67 Overnight 1/150 Polyclonal Ab anti-Ig-HRP AEC
BrdU Overnight 1/50 Polyclonal Ab anti-Ig-HRP DAB
CyclinD1 Overnight 1/150 Polyclonal Ab anti-Ig-HRP AEC
MAPK Overnight 1/125 Polyclonal Ab anti-Ig-HRP DAB
Akt Overnight 1/80 Polyclonal Ab anti-Ig-HRP AEC
AEC¼3-amino-9-ethylcarbazole; DAB¼3,30-Diaminobenzidine tetrahydrochloride.
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the human PTC cells, which are also different from the RET/PTC3
model.
Those histological findings were accompanied by changes in the
expression of proteins related to thyroid function, proliferation
indices, PKB and MAPkinase pathways.
Our results represent a precise histological description of the
follicular cell changes, hyperplastic and tumour features, followed
by corresponding data concerning thyroid function, cell prolifera-
tion, PKB and MAPkinase pathway indicators. The several
encountered modifications occurring in the transgenic models in
comparison with controls are described according to age.
Follicular cell changes
At 2 months, WT mouse thyroids harboured cuboidal follicular
cells lining small follicles (Figures 1A–C and 2A). The size of the
follicles became heterogeneous at 6 months, with dominant large
follicles lined by flat cells at 10 months (Figure 2B and C).
E7 thyroids were much larger than WT thyroids at all ages
(Figure 1D–F). At 2, 6, and 10 months, the follicular cells, with a
not well marked cellular border, were crowded and overlapping all
around the follicles, with a 1.9-fold cell number increase at 2
months in comparison with the WT (Figure 2A and D). The nuclei
were hyperchromatic with an increase in the nuclear/cytoplasmic
ratio (Figure 2D), The follicular border appeared ‘palissade like’
(Figure 2D–F). At 6 and 10 months huge follicles lined with flat
follicular cells (Figures 2E, F, 3B and Q) coexisted with small round
and irregularly shaped follicles with ‘palissade like’ borders
(Figures 2E, F, 3B and Q).
RET/PTC3 thyroids were larger than control thyroids at all ages
but smaller than those of the E7 model (Figure 1). The
modifications were different from one mouse to another.
At 2 months, part of the cells were modified; they were larger
(more than 8mm instead of 3mm), lining all or part of the thyroid
follicles, stratified in some areas (Figure 2G). The cytoplasm was
large with a convex apical border and a decreased nuclear/
cytoplasmic ratio, a pale nucleus, sometimes pleomorphic with
dispersed chromatin (Figure 2G). The nucleus location and
polarity were disturbed (Figure 2G). At 6 and 10 months, many
follicular cells were still large but some were not (Figure 2H and I).
Hyperplastic features
Absent in the WT, hyperplastic areas were present in both E7 and
RET/PTC 3 as micro or larger papillary infoldings with or without
secondary follicles. Present already in the 2-month models, these
papillae became more numerous with age, especially in the E7
model with a branching distribution, often situated in the centre of
the lobe inside dilated follicles (Figure 2D–F). In the RET/PTC3
model, the thyroid organisation was progressively replaced at 6
and 10 months, in 20% of the examined thyroids, by a cribriform
pattern difficult to distinguish in some cases from a true diffuse
tumour process (Figure 2H2). The cell changes already described
persisted in the two models at 6 and 10 months.
In 28% of the examined RET/PTC3 thyroids a peculiar pattern
emerged at 2 months. Thyroid lobes were totally replaced by a
series of large cysts filled with papillary structures more or less
coalescent, bordered with large cells, with rare nuclear cytoplasmic
pseudo inclusion (Figure 1J middle insert) and pleomorphism.
Peripheral cysts were filled with macrophages (Figure 1J). A
mixture of true mesenchymatous tissue and sheets of spindle or
more round cells, in close vicinity with the wall of the cyst or their
papillary content, existed between cysts (Figures 1J and 2G2). In
the absence of a true definition of this pattern in the literature,
we identify them as ‘proliferative papillary cystic changes with
spindle cells and remodeling’. They were rare at 6 months and
absent at 10 months.
Peripheral large cysts with a discrete micropapillary border
in an otherwise ‘normal’ or moderately hyperplastic thyroid
structures were encountered in 45 and 58% of the 6 and 10 months
thyroid RET/PTC 3 models respectively (Figures 2H1, 3D, I, N
and S).
Distinct tumours
They were absent in the WT and we did not find any in the E7
model. In the RET/PTC3 mice, true tumours were already visible in
16% of the cases, either at 6 months and most often at 10 months
(Figure 1I). These tumours (small foci around 1mm or macro-
scopically visible 5mm diameter tumour) were unique or multiple.
They were not or only partially circumscribed. The dominant
histological pattern was solid without an obvious follicular or
papillary structure. Cells harboured either a large cytoplasm
(Figure 2I) and oval nucleus or were spindle-like with less
cytoplasm (Figure 2I). Some mitoses were observed. The two
thyroid lobes of the same mouse could show different lesions,
mostly associated with the ‘cribriform pattern’ (Figures 1I and
2H2).
Thyroid function
WT mice At all ages Tg staining was observed in the follicular
lumen (Figure 3F). Radioiodine incorporation (Figure 3P) paral-
leled the immunostaining of Tg-I (Figure 3K). At 2 months the
follicles presented a high capability to bind radioiodide, which
decreased and disappeared in the follicles lined with flat cells at 6
and 10 months (Figure 3K and P). NIS was detected in a baso-
lateral position of the follicular cells at 2 months (not shown). This
uniformity decreased with age and NIS was absent in the flat cells
(Figure 3A).
2 months
WT
AB C
D E F
G H I
JK
W7
RET
RET
6months 10 months
Figure 1 Paraformaldehyde-fixed, paraffin-embedded and haematox-
ylin–eosin stained thyroid tissues from C57Bl/6, E7 and RET/PTC3. (A–C)
2, 6, and 10-month C57Bl/6 thyroids respectively; (D–F) 2-, 6-, 10-month
E7 thyroids respectively; (G–I) 2-, 6-, 10-month RET/PTC3 respectively,
(I) two lobes from the same mouse; (J and K) 2-, and 6-month RET/PTC3
with remodeling and cyst (diffuse sclerosing); upper right insert of J:
macrophages infiltration, middle right insert of J: nuclear inclusion; low right
insert of J: thick spindle-like cells in between follicles. Original magnification
2.5 . Scale bar: 1mm.
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(Figure 3G). Half of the follicles were labelled at 2 months for Tg-I
but the corresponding staining decreased at 6 and 10 months
(Figure 3L and Q). Tg-I persisted in the small round and irregular
shaped follicles and in the follicles close to the papillary infoldings
(Figure 3L). Autoradiography confirmed the limited localisation of
Tg-I (Figure 3Q). NIS was detected in the majority of thyroid
epithelial cells at 2 months and in the Tg-I-positive areas at 6 and
10 months. It disappeared in the flat cells (Figure 3B).
RET/PTC3 mice At 2 months, NIS was expressed only in the large
cells. The number of follicles positively labelled for Tg-I and
displaying radioiodine was systematically lower than in E7 and WT
mice. Tg was observed in all follicles. By 6 months and later, low
cuboidal-flat follicular cells displayed a rare expression of NIS, no
radioactive iodide incorporation (Figure 3C and R) and no Tg-I
immunostaining (Figure 3M) whereas Tg was still present
(Figure 3H). In the disorganised papillary regions at the periphery
of the gland, the modified follicular cells expressed NIS in a baso-
lateral position (Figure 3D). The lumen was devoid of iodide
uptake and Tg-I labelling. Tg only persisted as a lining at the apical
border of the follicular cells (Figure 3I, N and S).
In the solid tumour, NIS and Tg were situated in the cytoplasm
of the cells. The intensity of the staining varied from one region to
the other (Figure 3E and J). Tg-I was negative (Figure 3O).
Thyroid tumour growth
Measurements of Ki-67 and BrdU-labelling indexes showed the
same features. In WT, RET/PTC3, and E7 thyroids the overall
proliferation index was the highest at 2 months and decreased with
age. Compared with WT, the frequency of positive proliferation
indexes was systematically higher in both thyroid models and
higher in E7 than in RET/PTC3 at all ages (Table 2). In 2-month-
old E7 thyroids, the number of proliferating cells was increased
compared with WT (Table 3, Figure 4C and O) and homogenously
distributed. At 6 and 10 months, proliferating foci were mainly
located in small irregularly shaped follicles and papillae. Prolifera-
tion was very rare in flat cells (Table 3, Figure 4D and P).
In RET/PTC3 thyroids proliferating foci were often located in
the papillary infoldings and in the solid tumour (Table 3,
Figure 4F). Cyclin D1 immunolabelling paralleled the results
obtained with BrdU and Ki-67 (Table 3, Figure 4K and L).
In the E7 model, Cyclin D1 immunolabelling was very low in
follicular cells compared with WT, but was positive in the nucleus
of a great number of stromal cells. It was rarely positive in control
stroma (Table 3, Figure 4I and J). Some human thyroid nodular
goitre and differentiated thyroid carcinoma presenting morphol-
ogy and nuclear features (Figure 5A and C) similar to E7 mouse
model also showed stromal cell-positive staining for Cyclin D1
(Figure 5B and D). In mouse E7 model, no apoptosis, as measured
by Tunel assay and by immunohistochemical detection of activated
caspase 3, could be observed in thyrocytes of both transgenic
models and wild-type mice (not shown).
The PKB and MAP kinase pathways
At 2 months, phosphorylated PKB/Akt expression was cytoplas-
mic, slightly weaker in E7 (Figure 6C and D) than in RET/PTC3
(Figure 6E and F) and WT mice (Figure 56A and B). Staining
decreased at 6 months in WT thyroid, but was unchanged in RET/
PTC3 follicular cells (visible in some nuclei) (Figure 6B and F).
In WT thyroids phosphorylated MAPK showed a nucleo-
cytoplasmic staining that almost disappeared at 6 months (Figure
6G and H). In RET/PTC3 MAPK staining was stronger and
WT
E7
RET
6 months 2 months
A B
26 cells
2.6 µm
3.0 µm C
D E F
I
10 months
3.0 µm
43 cells
3 µm
3.0 µm 8.7 µm
1 µm
1.0 µm
3.1 µm
3.5 µm
10 µm
G1
G2 H1 H2
Figure 2 Haematoxylin–eosin stained C57Bl/6, E7 and RET/PTC3 thyroid glands. (A–C) wild type C57Bl/6 thyroids; (D–F) E7 thyroids; (G–I) RET/
PTC3 thyroids. Upper right inserts in A: WT nuclei, in B: E7 nuclei and upper left insert in G1: pale, pleomorphic with dispersed chromatin nuclei and
nuclear groove, red scale bar: 3mm (100 ), upper right insert in G1: large thyrocytes with a decreased ratio of nuclear/cytoplasm (0.27–0.55) compared
with WT (1.20) and E7 (3.97–22.67) thyrocytes, red bar equal to 8.7mm (40 ); (G2) 2-month RET/PTC3 with remodeling and cyst (diffuse sclerosing);
(H1) disorganised papillary cyst zone in 6-month RET/PTC3 thyroid. (H2) cribriform structures in RET/PTC3; upper insert: two small follicles share one part
of the follicular ‘wall’; (I) solid tumour structure in RET/PTC3, long arrow: cells harboured a large cytoplasm and oval nucleus, short arrow: spindle-like with
less cytoplasm. Original magnification  40 for A–I; scale bar: 30mm.
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months (Figure 6K and L). On the contrary, only a weak labelling
was found in the cytoplasm of E7 epithelial cells with the ‘palissade
like’ appearance and sometimes in their nucleus (Figure 6I and J).
DISCUSSION
As in previous studies on transgenic E7, and RET/PTC3 mouse
models (Ledent et al, 1995; Coppe ´e et al, 1996; Powell et al,1 9 9 8 ;
Portella et al, 2000) the generally encountered features such as
hyperplasia, and solid tumours in the RET/PTC3 model are present.
The cellular modification and the goitre present in the E7 model were
as already described. However, we do not find tumours in the E7
model, but our study ended earlier (10 months) than the other
studies. We do not find in the literature any precise description of the
cellular modification encountered in the RET/PTC3 model, nor fully
documented data on the several tested parameters we presented
(thyroid function, proliferative indices, pathway indicators). Some
studies tested thyroid function, as serum thyroid hormone level, or
tissue thyroglobulin expression (Ledent et al,1 9 9 5 ) .F e wo ft h et e s t e d
cell cycle indicators presented in our study have been tested.
M o r e o v e ro u rf i n d i n g so nc y c l i nD 1e x p r e s s i o ni na nE 7m o d e lh a v e
never been previously mentioned. In both models the PKB and
MAPkinase pathways were not analysed. However, the low rate of
tumour formation encountered in our study of the E7 or RET/PTC3
models differed from previous studies. In our E7 model, at 10
months, we do not find tumours, whereas a 15% occurrence of
carcinomas at 12 months was observed in the E7 model (Portella et al,
2000). In the RET/PTC3 model, Portella et al (2000) described 42% of
tumours at 12 months, Powell et al (1998), 55% at 6 months.
To explain such discrepancies, we can exclude a loss of
expression of the transgene. Its expression was constant from
one animal to the other and did not vary with age. Nevertheless,
within one thyroid, one could not assert a uniformity of expression
of the transgene all over the thyroid. The homology of the studied
strains in the different literature series must be discussed. A long
time duration exists between the generation of the two transgenic
WT 6 months
Nis
A
F G H I J
O N M L K
P Q R S
BCDE
Tg
Tg-I
RAD
E7 6 months RET/PTC 6 months RET/PTC 6 months RET/PTC 10 months (solid)
Figure 3 Immunohistochemistry for Sodium Iodide Symporter (NIS), Thyroglobulin (Tg), Iodinated-thyroglobulin (Tg-I) and incorporation of iodide
visualized by autoradiography (ARG). (A, F, K and P) 6-month C57Bl/6, NIS, Tg, Tg-I immunostaining and autoradiography, respectively; (B, G, L and Q)
6-month E7, NIS, Tg, Tg-I immunostaining and autoradiography, respectively; (C, H, M and R) 6-month RET/PTC3, NIS, Tg, Tg-I immunostaining and
autoradiography, respectively; (D, L, N and S) 6-month RET/PTC3, disorganized papillary cyst region NIS, Tg, Tg-I immunostaining and autoradiography
respectively; (E, J and O) 10-month RET/PTC3, solid mass region NIS, Tg, Tg-I immunostaining, respectively. Original magnification for (E, J and O):  10,
scale bar: 100mm. Original magnification for other images:  40; scale bar:30mm. Inserts magnification:  40.
Table 2 General table of dominant patterns in RET/PTC3 thyroids
RET/PTC3 n
Mild change
(MD)/hyperplasia
Papillary cystic proliferative changes
with spindle cells and
remodelling hyperplasia
Hyperplasia and
solid tumour
Cribriform
patterns
Cyst with
micropapillae
2 months 21 8 (MD)(38%)/7 (33%) 6 (28%) 0 0 0
6 months 20 8 (40%) 1 (5%) 2 (10%) 2 (10%) 9 (45%)
10 months 12 1 (8%) 0 3 (25%) 2 (16%) 7 (58%)
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ground present in both models, had declined with time due to a
backcross in our study with a C57Bl/6 wild type. This can probably
explain part of the differences with older series. This backcross
should represent a good opportunity to identify modifier genes in
the C57B1/6 genetic background responsible for the phenotype
changes. In addition, we cannot exclude terminological differences
as part of our discrepancies.
Our extensive study raises several points:
  the association in both models of peculiar cellular dysplastic changes
and hyperplasia which could be called ‘dysplastic hyperplasia’.
Table 3 Proliferation index in E7 and RET/PTC3 thyroid cell
E7 (n¼83)
Age of mice 2 months (n¼26) 6/10 months (n¼57)
Pathological changes Hyperplasia
Papillae and small
irregular follicles ‘‘palisade
like’’ border
Follicles cuboidal
cell Large follicles: flat cell
Height of follicular
cells (lm) 3.0lm 10.0lm 3.0lm 1.0lm
Cell cycle markers
Ki-67 368.19% (WT 17.27%) 317.70% (WT 8.26%) 67.20% (WT 8.26%) 8.20% (WT 8.26%)
Cyclin D1
Thyrocytes 0.143%(WT 11.1%) 0.275%(WT 2.25%)
Stromal cells 21.81% 33.79% 10.55% 3.87%
BrdU 44% (WT 3.7%) 14.23% (WT 0.4%) 5.29% (WT 0.4%) 0.43% (WT 0.4%)
RET/PTC3 (n¼53)
Age of mice 2 months 6/10 months
Pathological changes Mild change/
hyperplasia
Papillary cystic with
spindle cells and remodeling
Mild changes Hyperplasia,
cribriform patterns
Cysts with
micropapillae
Solid mass
region
Height of follicular
cells (lm)
1.6-8.9lm 1.6-8.9lm 1.6-3.1lm 3.1-8.9lm 3.1-8.9lm NE*
Cell cycle markers
Ki-67 29.96% 86.01% 3.98% 30.28% 33.08% 62.44%
Cyclin D1 95% 220% 1.6% 20% 201% 203%
BrdU 7.8% 34% 0.6% 7.0% 13% NE
NE¼not examined. NE* the heterogeneity of the cellular component (size and shapes) does not permit any measurement. The proportion of epithelial cells labeled was
estimated as per thousand (%) of the total number of thyrocytes, and presented as mean values±s.e.m. For scoring, at least a thousand thyrocytes on two different slides were
counted in one mouse thyroid.
Ki-67 2 months
WT
AB GH M N
CDI J OP
EF KL QR
E7
RET
Ki-67 6 months Cyclin D1 2 months Cyclin D1 2 months BrdU 2 months BrdU 6 months
Figure 4 Immunohistochemistry for Ki-67 (A–F), Cyclin D1 (G–L) and BrdU stainings (M–R) in thyroid tissues from C57Bl/6, E7 and RET/PTC3. (A, G
and M) 2-month C57Bl/6; (B, H and N) 6-month C57Bl/6; (C, I and O) 2 month E7; (D, J and P) 6-month E7; (E, K and Q) 2-month RET/PTC3; (F, L and
R) 6-month RET/PTC3. Upper left part of (F) and upper right corner of (L): solid mass regions. (R): disorganized papillary tumour region. Original
magnification:  40; scale bar: 30mm.
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cribriform patterns and the ‘proliferative papillary cystic
changes with spindle cells and remodeling’ is not mentioned
by others. However, the picture obtained in our study
corresponds to some of the descriptions by Powell et al
(1998); Powell et al (1998) define PTC ‘as cellular nodules
adjacent to, or extending into colloid filled follicles’; Russell et al
(2000) define carcinoma as: ‘more than 50 thyroid follicular
epithelial cells clustered together with a homogeneous appear-
ance. Epithelial cell clusters may form a continuous sheet or
papillae that surround a fibro-vascular stalk. The nucleus may
be either homogeneous or pleiomorphic’. No precisions are
added considering whether or not those cell proliferations are
inside a follicle. In human pathology, a diagnosis of thyroid
carcinoma would not be accepted on such criteria, for example
when the proliferation is included in a follicle, even if distended.
Akt 2 months
WT
AB
C D
EF KL
IJ
GH
E7
RET
Akt 6 months MAPK 2 months MAPK 6 months
Figure 6 Immunohistochemistry for p-PKB/Akt (A–F) and p-MAPK (G–L) in thyroid tissues from C57Bl/6, E7 and RET/PTC3. (A and G) 2-month
C57Bl/6; (B and H) 6-month C57Bl/6; (C and I) 2-month E7; (D and J) 6-months E7; (E and K) 2-month RET/PTC3; (F and L) 6-month RET/PTC3.
Original magnification:  100; scale bar: 30mm.
H&E
Human
DTC
Human
TNG
Cyclin D1
AB
D C
Figure 5 Haematoxylin–eosin and Cyclin D1 immunohistochemistry stainings of A and B: human differentiated thyroid carcinoma; (C and D) Human
thyroid nodular goitre. Upper right inserts in A and C: small thyrocytes with high nuclear/cytoplasm ratio. Arrows in B and D: positive stromal cell nuclei for
Cyclin D1. Original magnification:  20 for A;  60 for B;  4 for C and  40 for D.
Pathological thyroid phenotype of Tg-E7 and RET/PTC3
L Jin et al
1880
British Journal of Cancer (2008) 99(11), 1874–1883 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sA similar confusion arises when the solid-type papillary
carcinoma occurring in RET/PTC 3 transgenic mice is considered
as an equivalent of the solid PTC variant found in radiation-
induced thyroid cancer of children harbouring an RET/PTC3
rearrangement (Powell et al, 1998; Thomas et al, 1999). The
encountered mouse features are very far from the solid human
variant in which the tumour cells with PTC nuclear features are
still round, organised in sheets or trabeculae of variable size, with a
tendency to keep follicular patterns, even rudimentary.
The solid pattern described in transgenic mice is not specifically
induced by RET/PTC3 oncogene. Several transgenic mouse
models, either RET/PTC1 (Jhiang et al, 1996), RET/PTC3 (Powell
et al, 1998; Portella et al, 2000), TRK-T1 (less often) (Russell et al,
2000), A2aR/E7 (Coppe ´e et al, 1996) and so on, develop solid
tumours. Certain conditions favoured the occurrence of a solid
phenotype: TSH stimulation of RET/PTC1 model (Sagartz et al,
1997), double transgenic mice RET/PTC3 P53 /53  (La Perle
et al, 2000; Powell et al, 2001). Other conditions prevent it such as
the double transgenic model RET/PTC3-E7 (Portella et al, 2000).
The RET rearrangement, either RET/PTC1 or RET/PTC3, looks
as a facilitator in the development of spindle cells in transgenic
mice at early stage (Cho et al, 1999), or later on (Williams, 1994;
Sagartz et al, 1997). The association with a cribriform pattern is
also mentioned in the RET/PTC1 mouse model (Jhiang et al, 1996).
Pictures from RET/PTC3 and RET/PTC1 solid variants show some
differences; large proliferative spindle cell areas with less visible
cytoplasm are more developed in the RET/PTC3 model (Sagartz
et al, 1997; Powell et al, 1998).
In the human series of Nikiforov et al (1997), RET/PTC3
tumours are solid, PTC classical, follicular, or a diffuse sclerosing
variant. In the adult series of Basolo et al (2002), one-third is
tall cell PTC, as in part of the Nakazawa et al (2005) PTC series.
We cannot precisely determine whether or not our solid
mouse tumour corresponds to a PTC with a spindle-cell metaplasia
as described in human PTC (Vergilio et al, 2002) or to a
progressive transformation in a less differentiated phenotype
(Bronner and LiVolsi, 1991; Brandwein-Gensler et al, 2004).
Favouring this last hypothesis, the morphology of these solid
tumours is heterogeneous, unlike the homogeneous description
mentioned in early literature (Powell et al, 1998). Indeed in these
areas one observes a modified NIS, Tg, and TTF-1 immuno-
labelling and high proliferation indices, as in human aggressive
tumours.
The association of cribriform tumour patterns and spindle cells
is described in the columnar human PTC (Wenig et al, 1998)
without any knowledge of the RET/PTC3 status, and in the
morular/cribriform PTC (Harach et al, 1994; Cetta et al, 1999).
This last entity, sporadic or associated with the Familial
Adenomatous Polyposis syndrome, has been studied at the
molecular level, which revealed an APC germline mutation
associated with somatic RET/PTC3 oncogene rearrangement
(Soravia et al, 1999).
‘The proliferative papillary cystic changes with spindle cells and
remodeling pattern’, which emerged at a quite early age of 2
months in our RET/PTC3 model is puzzling. The number of such
phenotypes decreased at 6 months and totally disappeared at 10
months. We wonder whether it may correspond to the rare human
young age ‘diffused sclerosing’ variant (Chow et al, 2003), with its
mesenchymal remodeling and inflammatory background, or as
found by Russell et al (2004) in the RET/PTC3 mouse in the strain
background C57 BL/6.
In both RET/PTC3 and E7 transgenic mouse thyroids, the ability
to concentrate radioiodide is generally reduced as in human
thyroid carcinomas (Ge ´rard et al, 2003).
In the disorganised papillary cystic regions of the RET/PTC3
model, NIS is overexpressed, but not Tg-I, and there is no
iodide uptake. This can be correlated with data in the human PTC.
It could be due to an increased intracellular NIS misexpression
(Saito et al, 1998; Wapnir et al, 2003; Riesco-Eizaguirre and
Santisteban, 2006), to conformational changes (Ge ´rard et al, 2003)
or to the non maturation of hNIS (Trouttet-Masson et al, 2004).
RET stimulates MAPK and Akt/PKB-signalling pathways,
through Ras-Raf-Merk-Erk, Ras-PI3-K/Akt/PKB in vivo and vitro
(Melillo et al, 2005; Mitsutake et al, 2006; Santoro et al, 2006).
Activated Akt/PKB prevents apoptotic death in many cell types
(Brunet et al, 1999). This probably explains why almost no
apoptotic cell was detected in our RET/PTC mice.
In RET/PTC3 mouse thyroids, a strong labelling of phosphory-
lated MAPK in nuclei of the large cells and the cells in solid mass
suggests a marked stimulation of the MAPK pathway. It parallels
the same findings in the rat RET/PTC3-transfected thyroid cell line
(Basolo et al, 2002).
Apart from these pathological features the transgenic models
raise several interesting functional points. Double transgenic mice
of RET/PTC3 and E7, and A2R and E7 showed that E7-mediated
thyroid phenotype is dominant (Coppe ´e et al, 1998; Portella et al,
2000). E7 oncogene acts downstream of RET/PTC3, and directly
binds and inhibits RB1 protein and/or related proteins, therefore
relieving their inhibition of transcription factors E2Fs (Ledent,
1996; Dyson, 1998; Helin, 1998). This could explain the scarcity of
thyrocytes nuclei positive for Cyclin D1. It suggests that Cyclin D1
expression in thyroid epithelium of the E7 cells is inhibited by a
negative feedback of the Cyclin D1-RB1-E2F1 axis. The cyclin D1
staining of stromal cells (not seen in WT and RET/PTC3 thyroids)
is puzzling and not reported in human thyroid carcinomas (Wang
et al, 2000). However, we have identified such features in human
thyroid goitres, and in malignant tumours with ‘E7 like’ cellular
features. It suggests that stromal cells get direct or indirect
autocrine or paracrine signals from E7-expressing thyroid
epithelium.
The activation level of the MAP kinase and Akt/PKB was
different between E7 and RET/PTC3 trangenic models. E7 acts
downstream of these pathways and therefore does not activate
them. E7 relieves the cell of any necessity of RB phosphorylation
by cyclin-dependent kinases CDK. PKB/Akt cytoplasm staining
evokes the maintenance by an unknown mechanism of a weak
phosphorylation, which might prevent apoptosis.
Differences between thyroid cancer prone mouse strains have
been demonstrated by others (Knostman et al, 2007). In our
thyroid transgenics this phenomenon might explain strain-to-
strain alterations (Russell et al, 2004; Knostman et al, 2007) as well
as a detectable background of thyroid neoplasia.
Nevertheless the models allow a kinetic in vivo model of the
process of tumorigenesis by the oncogenes. Gene expression study
by microarray technology has shown that important biological
processes are differently regulated in the two tumour models: in E7
thyroid cells overexpression of cell cycle genes constitutes the most
upregulated process whereas RET PTC3 thyroid cells present an
upregulation of human PTC markers, of EGF-like growth factors,
and extracellular remodeling genes (Burniat et al, 2008). Simila-
rities with human PTC are observed at a young age but are
incomplete. Therefore RET/PTC3 tumours are partial and transient
models of human PTC. These results are now confirmed at a
histological level with two different morphofunctional phenotypes:
one with small cell looking like both primordial and differentiated,
the other with large cells. A later study of gene expression in laser-
microdissected areas will allow to characterize the molecular
phenotype of these variants.
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